DNTH
Dianthus Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$101.00-4.36%
Price as of Jul 20, 2026
DNTH financials
Dianthus Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $2.0M | $6.2M | $2.8M | $6.4M |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $2.0M | $6.2M | $2.8M | $6.4M |
| Operating expenses | $180.0M | $108.1M | $51.0M | $36.1M |
| Operating income | -$177.9M | -$101.9M | -$48.2M | -$29.7M |
| Net income | -$162.3M | -$85.0M | -$43.6M | -$28.5M |
| EBITDA | -$161.9M | -$84.6M | -$43.2M | -$28.3M |
| Basic EPS | $-4.20 | $-2.55 | $-8.45 | $-7.60 |
| Diluted EPS | $-4.20 | $-2.55 | $-8.45 | $-7.60 |
| Balance sheet | ||||
| Cash & equivalents | $51.1M | $22.8M | $132.3M | $15.4M |
| Total assets | $530.9M | $374.0M | $179.4M | $83.1M |
| Total liabilities | $37.5M | $21.5M | $10.5M | $9.5M |
| Stockholders’ equity | $493.4M | $352.5M | $168.9M | $73.7M |
| Total debt | $1.4M | $1.5M | $585.0K | $788.0K |
| Net debt | -$49.7M | -$21.3M | -$131.7M | -$14.6M |
| Cash flow | ||||
| Operating cash flow | -$129.1M | -$78.2M | -$36.9M | -$29.1M |
| Capital expenditure | -$213.0K | -$105.0K | -$110.0K | -$139.0K |
| Free cash flow | -$129.3M | -$78.3M | -$37.0M | -$29.2M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |